The global oncology market is forecasted to reach $111.9 billion by 2020, registering a CAGR of 7.1% from 2014 to 2020, according to a new report by Allied Market Research, titled Global Oncology/Cancer Drugs Market—Size, Industry Analysis, Trends, Opportunities, Growth and Forecast, 2013-2020.
An increase in adoption of combination therapies instead of traditional cytotoxic therapies is a major factor contributing to the market growth. Combination therapies, which include targeted therapy and immunotherapy (biologics therapy), are expected to witness an approximate 10% surge in market share collectively by 2020.
Augmentation in the prevalence and incidence rate of various cancers, growing popularity of biological and targeted modalities, along with the patent expiration of major cancer drugs, are expected to drive the growth of global oncology drugs market. However, high initial capital investment for new drug development, long-term side effects associated with chemotherapy and high cost of advanced therapies (targeted and immunotherapies) would limit the growth of the market.
The global oncology drugs market is experiencing a shift in therapeutic modalities, i.e., from traditional cytotoxic agents to newly develop targeted and immunotherapeutic modalities. Tumor cell specificity, an attribute of aforementioned modality, has reduced drug remission rates and has rendered an enhanced rate of survival in cancer patients, thus complementing the market growth. However, chemotherapeutic modalities would continue to be the leading therapeutic modality segment owing to its higher adoption rate and economic pricing. Going forward, the demand for the chemotherapy modality might confront a negative influence due to marginal efficacy and chronic side effects such as anemia.
Geographically, the developed economies such as North America and Europe collectively accounted for approximately 65% of market share in 2014, due to higher adoption rates and advanced hospital settings. However, developing economies are expected to experience potential opportunities owing to the emergence of biosimilars in monoclonal antibodies and improved medical infrastructure.
Key findings of the study:
A majority of the oncology drug manufacturers have adopted collaboration and acquisition as key developmental strategies to achieve a competitive edge. Moreover, companies also are forming strategic alliances to accelerate the process of clinical trials. These strategies have proved to be effective in helping key market players retain their leading positions in the global oncology drugs market.
Allied Market Research is a full-service market research and business-consulting wing of Allied Analytics, based in Portland, Ore.